SEC Comment Letter for PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Dec 23, 2019
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Dec. 23, 2019 · CIK: 0001472091 · Accession: 0000000000-19-016765
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235549
Letter
December 23, 2019 Frank K. Bedu-Addo, Ph.D. President and Chief Executive Officer PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540 Re:PDS Biotechnology Corporation Registration Statement on Form S-1 Filed December 17, 2019 File No. 333-235549 Dear Dr. Bedu-Addo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Fahd. M.T. Riaz, Esq.
Show Raw Text
December 23, 2019
Frank K. Bedu-Addo, Ph.D.
President and Chief Executive Officer
PDS Biotechnology Corporation
303A College Road East
Princeton, NJ 08540
Re:PDS Biotechnology Corporation
Registration Statement on Form S-1
Filed December 17, 2019
File No. 333-235549
Dear Dr. Bedu-Addo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Fahd. M.T. Riaz, Esq.